---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-004648"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:58:51.255253+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Precigen posts FY2025 net loss of $1.37/sh; PAPZIMEOS Q4 revenue $3.4M, launch momentum strong

## Summary
- PAPZIMEOS generated $3.4M in net product revenue in Q4 2025, first partial quarter of US commercial sales.
- Cash, cash equivalents, and investments $100.4M as of Dec 31, 2025, expected to fund to cash flow break-even.
- Patient hub enrollment >300; payer coverage ~215M lives (~90% insured US); CMS assigned permanent J-code effective Apr 1, 2026.
- Net loss attributable to common shareholders $429.6M ($1.37/sh) vs $126.2M ($0.47) in 2024, driven by non-cash warrant and preferred stock items.
- R&D expenses down 22.1% YoY; SG&A up 69.8% reflecting commercial launch investment.

## SEC filing metadata
- accession: 0000950103-26-004648
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010326004648/0000950103-26-004648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010326004648/dp244075_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-004648
- JSON: https://secwatch.observer/filing/0000950103-26-004648.json
- Plain text: https://secwatch.observer/filing/0000950103-26-004648.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.